HK1109088A1 - Solubilization preparation - Google Patents
Solubilization preparationInfo
- Publication number
- HK1109088A1 HK1109088A1 HK08103361.7A HK08103361A HK1109088A1 HK 1109088 A1 HK1109088 A1 HK 1109088A1 HK 08103361 A HK08103361 A HK 08103361A HK 1109088 A1 HK1109088 A1 HK 1109088A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- solubilization preparation
- solubilization
- preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title 1
- 230000007928 solubilization Effects 0.000 title 1
- 238000005063 solubilization Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005172725 | 2005-06-13 | ||
| PCT/JP2006/311739 WO2006134864A1 (ja) | 2005-06-13 | 2006-06-12 | 可溶化型製剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1109088A1 true HK1109088A1 (en) | 2008-05-30 |
Family
ID=37532226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK08103361.7A HK1109088A1 (en) | 2005-06-13 | 2008-03-26 | Solubilization preparation |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8283352B2 (ja) |
| EP (1) | EP1891956B1 (ja) |
| JP (1) | JP4866349B2 (ja) |
| KR (1) | KR101328857B1 (ja) |
| CN (1) | CN101198331B (ja) |
| ES (1) | ES2390353T3 (ja) |
| HK (1) | HK1109088A1 (ja) |
| WO (1) | WO2006134864A1 (ja) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010151711A1 (en) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
| CA2798172C (en) | 2010-01-07 | 2017-11-21 | Alkermes Pharma Ireland Limited | Quaternary ammonium salt prodrugs |
| US20110166156A1 (en) * | 2010-01-07 | 2011-07-07 | Alkermes, Inc. | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease |
| US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
| RU2529800C2 (ru) * | 2010-03-18 | 2014-09-27 | ИННОФАРМА, Инк. | Стабильные составы бортезомиба |
| CA2814840C (en) * | 2010-10-18 | 2018-08-28 | Dainippon Sumitomo Pharma Co., Ltd. | Sustained-release formulation for injection |
| US8258139B2 (en) * | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
| WO2012105715A1 (en) * | 2011-02-02 | 2012-08-09 | Dainippon Sumitomo Pharma Co., Ltd. | Novel external preparation |
| WO2012107890A2 (en) * | 2011-02-10 | 2012-08-16 | Ranbaxy Laboratories Limited | Crystalline forms of lurasidone hydrochloride |
| HRP20240285T1 (hr) * | 2011-03-18 | 2024-05-24 | Alkermes Pharma Ireland Limited | Farmaceutski pripravci koji sadrže sorbitan estere |
| WO2012156981A1 (en) * | 2011-05-13 | 2012-11-22 | Cadila Healthcare Limited | Pharmaceutical compositions of lurasidone |
| CN102793701B (zh) * | 2011-05-25 | 2014-12-17 | 上海医药工业研究院 | 卢拉西酮组合物 |
| JO3190B1 (ar) * | 2011-10-19 | 2018-03-08 | Otsuka Pharma Co Ltd | محلول للتناول عن طريق الفم |
| CN103130795A (zh) * | 2011-12-02 | 2013-06-05 | 苏州二叶制药有限公司 | 卢拉西酮盐酸盐的晶体a及其用途 |
| ES2715562T3 (es) | 2011-12-15 | 2019-06-04 | Alkermes Pharma Ireland Ltd | Profármacos de compuestos de amina secundaria |
| NZ630643A (en) | 2012-03-19 | 2017-08-25 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising fatty acid esters |
| US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| US9993556B2 (en) | 2012-03-19 | 2018-06-12 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty glycerol esters |
| CN102688189B (zh) * | 2012-06-21 | 2014-10-29 | 北京鑫开元医药科技有限公司 | 一种鲁拉西酮药物组合物和制法 |
| WO2014080285A2 (en) | 2012-09-19 | 2014-05-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| BR112016021535A8 (pt) | 2014-03-20 | 2021-07-20 | Alkermes Pharma Ireland Ltd | kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso |
| EP3154967B1 (en) | 2014-06-16 | 2020-07-29 | Johnson Matthey Public Limited Company | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates |
| CN104606133A (zh) * | 2015-01-07 | 2015-05-13 | 万特制药(海南)有限公司 | 鲁拉西酮口服混悬液及其制备方法 |
| WO2017119928A1 (en) * | 2016-01-08 | 2017-07-13 | Abon Pharmaceuticals, Llc | Long acting injectable formulations |
| WO2018015915A1 (en) | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
| JPWO2018043613A1 (ja) * | 2016-08-31 | 2019-06-24 | 大日本住友製薬株式会社 | 水性懸濁型製剤 |
| EP3760206A4 (en) | 2018-02-28 | 2021-11-03 | Sumitomo Dainippon Pharma Co., Ltd. | AQUEOUS SUSPENSION TYPE PHARMACEUTICAL PREPARATION WITH CONTROLLED DISSOLUTION |
| JPWO2019167977A1 (ja) | 2018-02-28 | 2021-02-04 | 大日本住友製薬株式会社 | 水性懸濁型医薬製剤 |
| AU2019230014A1 (en) | 2018-03-05 | 2020-09-17 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| WO2019213286A1 (en) * | 2018-05-02 | 2019-11-07 | LifeMax Laboratories, Inc. | Extended release suspension formulation of lurasidone |
| WO2022183196A1 (en) | 2021-02-24 | 2022-09-01 | Oakwood Laboratories, Llc | Microsphere formulations comprising lurasidone and methods for making and using the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2800953B2 (ja) * | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| KR100360827B1 (ko) * | 1999-08-14 | 2002-11-18 | 주식회사 삼양사 | 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법 |
| CA2425367A1 (en) * | 2000-08-30 | 2003-04-07 | Chugai Seiyaku Kabushiki Kaisha | Oct formulations |
| DE60138722D1 (de) * | 2000-09-22 | 2009-06-25 | Dainippon Sumitomo Pharma Co | Orale zubereitungen mit vorteilhaften zerfallseigenschaften |
| JP2003176228A (ja) | 2001-12-11 | 2003-06-24 | Rohto Pharmaceut Co Ltd | 液 剤 |
| WO2004113333A1 (ja) * | 2003-06-23 | 2004-12-29 | Dainippon Sumitomo Pharma Co., Ltd. | 老人性痴呆症治療剤 |
| ATE543817T1 (de) * | 2003-07-29 | 2012-02-15 | Dainippon Sumitomo Pharma Co | Verfahren zur herstellung einer imidverbindung |
| EP2357474A1 (en) | 2004-02-20 | 2011-08-17 | Dainippon Sumitomo Pharma Co., Ltd. | Lurasidone for use in the treatment of memory or learning dysfunction by schizophrenia |
| WO2006096439A2 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
-
2006
- 2006-06-12 WO PCT/JP2006/311739 patent/WO2006134864A1/ja active Application Filing
- 2006-06-12 US US11/922,015 patent/US8283352B2/en not_active Expired - Fee Related
- 2006-06-12 ES ES06766601T patent/ES2390353T3/es active Active
- 2006-06-12 EP EP06766601A patent/EP1891956B1/en not_active Not-in-force
- 2006-06-12 JP JP2007521271A patent/JP4866349B2/ja active Active
- 2006-06-12 KR KR1020077028359A patent/KR101328857B1/ko not_active IP Right Cessation
- 2006-06-12 CN CN2006800210272A patent/CN101198331B/zh not_active Expired - Fee Related
-
2008
- 2008-03-26 HK HK08103361.7A patent/HK1109088A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR101328857B1 (ko) | 2013-11-13 |
| CN101198331A (zh) | 2008-06-11 |
| JP4866349B2 (ja) | 2012-02-01 |
| US20090286805A1 (en) | 2009-11-19 |
| WO2006134864A1 (ja) | 2006-12-21 |
| JPWO2006134864A1 (ja) | 2009-01-08 |
| ES2390353T3 (es) | 2012-11-12 |
| EP1891956B1 (en) | 2012-08-29 |
| EP1891956A1 (en) | 2008-02-27 |
| KR20080024118A (ko) | 2008-03-17 |
| CN101198331B (zh) | 2012-05-02 |
| EP1891956A4 (en) | 2010-12-01 |
| US8283352B2 (en) | 2012-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1109088A1 (en) | Solubilization preparation | |
| GB2424581B (en) | Formulations | |
| IL192084A0 (en) | Vaccine | |
| GB0504436D0 (en) | Vaccine | |
| IL186521A0 (en) | Nanoparticle-active ingredient conjugates | |
| IL187919A0 (en) | 4c | |
| EP1909584A4 (en) | PRENYLFLAVONOID FORMULATIONS | |
| IL191774A0 (en) | Solid preparation | |
| ZA200709518B (en) | Vaccine composition | |
| EP1897558A4 (en) | SOLID PREPARATION | |
| IL185773A0 (en) | Formulations | |
| GB0519871D0 (en) | Immunogenic agents | |
| GB0515135D0 (en) | Vaccine | |
| ZA200709207B (en) | Vaccine | |
| GB0516944D0 (en) | Vaccine | |
| GB0810662D0 (en) | Vaccine | |
| ZA200709210B (en) | Vaccine | |
| GB0526412D0 (en) | Vaccine | |
| GB0518878D0 (en) | Formulations | |
| GB0520388D0 (en) | Formulations | |
| GB0522917D0 (en) | Formulations | |
| GB0526322D0 (en) | Formulations | |
| IL186591A0 (en) | Vaccine | |
| GB0511475D0 (en) | Vaccine | |
| GB0513191D0 (en) | Vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160612 |